Wired for What’s Next.
Reach your press release and disclosure targets.
Get more views with multimedia.
Track your results and refine your message.
Be the news everyone talks about.
Latest News
Today is September 18, 2021.
All times in Eastern Daylight Time.
-
Společnost Zynga představuje ReVamp, první společenskou hru pro více hráčů pro Snapchat
SAN FRANCISCO--(BUSINESS WIRE)--Společnost Zynga Inc. (Nasdaq: ZNGA), světový lídr v oblasti interaktivní zábavy, dnes oznámila, že ReVamp, připravovaná společenská hra pro více hráčů, bude brzy uv... more » -
未来に適応した経営モデルを当フォーラムに求めるべき理由
中国・青島--(BUSINESS WIRE)--（ビジネスワイヤ） -- 賢者は常に一歩先を行き、社会の発展を導こうとします。今回注目されたのは、東洋の海辺の都市、青島でした。 モノのインターネット（IoT）は、経済や社会のあり方をかつてないスピードと方法で変えています。従来の開発モデルは、次々と現れるユーザーのニーズに対応できません。古典的な経済理論に言う「人」の道具化が進んだことで貧富の... more »
-
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with a choice of chemotherapies, etoposide plus either ... more » -
IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with a choice of chemotherapies, etoposide plus either ... more » -
N2 Packaging Systems, LLC élargit son portefeuille international de brevets pour le conditionnement du cannabis.
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--N2 Packaging Systems, LLC ("N2 Packaging") annonce que l'Office de la propriété intellectuelle du Canada [OPIC] a attribué le brevet N2 n° 3 077 777 pour un ense... more » -
Unifrax organiza la ceremonia de inauguración para la línea de producción de SiFAB™
NEW CARLISLE, Ind.--(BUSINESS WIRE)--En el día de hoy, Unifrax, un fabricante líder de materiales especializados de alto rendimiento, llevó a cabo una ceremonia para celebrar su primera línea de pr... more » -
Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 ... more » -
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck’s KEYTRUDA Demonstrated Superior Recurrence-Free Survival in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo more » -
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiic... more » -
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck’s KEYTRUDA Plus Chemo ± Bev Reduced Risk of Death by 33% Vs Chemo ± Bev as Treatment for Persistent, Recurrent or Metastatic Cervical Cancer more » -
ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Reduced the Risk of Disease Progression or Death by 72% vs. Trastuzumab Emtansine in Patients with HER2 Positive Metastatic Breast Can... more » -
Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data at ESMO Congress 2021. more » -
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Detailed primary results from the positive Phase II DESTINY-Lung01 trial of ENHERTU® (fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo Company... more » -
ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer more » -
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib (CABOMETYX®) in combinat... more »